<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02014805</url>
  </required_header>
  <id_info>
    <org_study_id>POCRT</org_study_id>
    <nct_id>NCT02014805</nct_id>
  </id_info>
  <brief_title>Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma</brief_title>
  <official_title>A Multi-institutional, Randomized Controlled Trial of Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>309th Hospital of Chinese People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether postoperative conformal radiotherapy are
      effective in the treatment of Masaoka stage II-III B type thymoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of postoperative radiotherapy in thymoma is controversial. Some retrospective
      studies were for the radiotherapy, but others were against. However, more inherent biases
      existed in these trials. Resection, Masaoka stage and pathology were widely accepted as the
      prognostic factors for thymoma. Furthermore, the frequency of local failure after radical
      resection was still high in Masaoka stage II-III B type thymoma. With the conformal technique
      appearing, conformal radiotherapy can escalate the dose without increasing the risk of normal
      tissue toxicities.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 year local control rate</measure>
    <time_frame>3 year after the end of all enrollment</time_frame>
    <description>local control: tumor recurrence in the tumor bed 3 year local control rate: number of patients with tumor recurrence in the tumor bed at 3 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3 year failure-free and overall survival</measure>
    <time_frame>3 year after the end of all enrollment</time_frame>
    <description>failure-free survivail: the interval from the surgery and the recurrence within or out the tumor bed overall survival: the interval from the surgery and the death or lost of follow-up</description>
  </secondary_outcome>
  <other_outcome>
    <measure>toxicity</measure>
    <time_frame>within 3 year after the end of all enrollment</time_frame>
    <description>toxicity: including the acute radition-induced lung toxicity and the late lung toxicity at 1, 3, 6, 9, 12, 18, 24, 30 and 36 month after radiation or observation</description>
  </other_outcome>
  <other_outcome>
    <measure>quality of life</measure>
    <time_frame>within 3 years after all enrollment</time_frame>
    <description>quality of life: FACT-Lung and EORTC QOL C30 before and after radiation, and at 1, 3, 6, 9, 12, 18, 24, 30, 36 months after radiation or observation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Thymoma</condition>
  <arm_group>
    <arm_group_label>radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no treatment after radical resection for thymoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma</description>
    <arm_group_label>radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75, Zubrod-ECOG-WHO 0-2, the interval of surgery to radiotherapy &lt; 2months,
             Masaoka stage II-III and WHO B type thymoma

        Exclusion Criteria:

          -  No second primary tumor, no serious comorbidity, no neoadjuvant anticancer treatment,
             no adjuvant chemotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qinfu Feng, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qinfu Feng, M.D.</last_name>
    <phone>8610-87788503</phone>
    <email>13811300221@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ye Zhang, M.D.</last_name>
    <phone>8610-87788504</phone>
    <email>drzye1983@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer hospital, Chineses Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuting Li, Ph.D.</last_name>
      <phone>8610-87788495</phone>
      <email>cancergcp@163.com</email>
    </contact>
    <investigator>
      <last_name>Qinfu Feng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2013</study_first_submitted>
  <study_first_submitted_qc>December 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2013</study_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Ye Zhang</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <keyword>postoperative</keyword>
  <keyword>conformal</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>thymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

